2cureX AB (publ) announced the approval from the Ethical Committee at Fundacion Jimenez Diaz in Madrid to start a clinical trial using IndiTreat? in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in metastatic colorectal cancer patients. An IndiTreat®?

test for this innovative treatment approach will bring additional value to 2cureX's ZENITH project for enabling in-house IndiTreat®? testing at hospital sites. Understanding HIPEC.

HIPEC (short for hyperthermic intraperitoneal chemotherapy) is an advanced treatment procedure designed to address cancer metastases in the abdomen. HIPEC procedures comprise the rinsing of the abdominal cavity with heated chemotherapy solutions after surgery. This targeted approach allows for higher local concentrations of chemotherapy with the intention to maximize effectiveness while minimizing systemic side effects.

This treatment is primarily offered to patients with cancers originating in the abdominal area, including colorectal cancer, gastric cancer, ovarian cancer, and mesothelioma. HIPEC approaches have shown promising results in increasing survival rates and improving the quality of life for patients with these challenging diagnoses. In this prospective trial, 2cureX's IndiTreat®?

tests will identify the cytotoxic drug that has the most promising efficacy profile on an individual HIPEC patient's tumor.